Henrik C Hansen
Overview
Explore the profile of Henrik C Hansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
387
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Melin L, Gesner E, Attwell S, Kharenko O, van der Horst E, Hansen H, et al.
ACS Omega
. 2021 Sep;
6(33):21327-21338.
PMID: 34471737
PB1 is a bromodomain-containing protein hypothesized to act as the nucleosome-recognition subunit of the PBAF complex. Although PB1 is a key component of the PBAF chromatin remodeling complex, its exact...
2.
Melin L, Calosing C, Kharenko O, Hansen H, Gagnon A
Bioorg Med Chem Lett
. 2021 Jun;
47:128208.
PMID: 34146702
BPTF (bromodomain and PHD finger containing transcription factor) is a multidomain protein that plays essential roles in transcriptional regulation, T-cell homeostasis and stem cell pluripotency. As part of the chromatin...
3.
Kharenko O, Patel R, Brown S, Calosing C, White A, Lakshminarasimhan D, et al.
J Med Chem
. 2018 Aug;
61(18):8202-8211.
PMID: 30165024
BET proteins are key epigenetic regulators that regulate transcription through binding to acetylated lysine (AcLys) residues of histones and transcription factors through bromodomains (BDs). The disruption of this interaction with...
4.
Kharenko O, Hansen H
Drug Discov Today Technol
. 2017 Dec;
24:19-24.
PMID: 29233295
Inhibition of bromo and extra-terminal (BET) bromodomains, including BRD4, has emerged as a new exciting epigenetic target for oncology, in particular. Recently, novel alternatives to the traditional use of reversible...
5.
Jahagirdar R, Attwell S, Marusic S, Bendele A, Shenoy N, McLure K, et al.
Mol Pharmacol
. 2017 Oct;
92(6):694-706.
PMID: 28974538
Bromodomain (BD) and extra-terminal domain containing proteins (BET) are chromatin adapters that bind acetylated histone marks via two tandem BDs, BD1 and BD2, to regulate gene transcription. BET proteins are...
6.
Kharenko O, Gesner E, Patel R, Norek K, White A, Fontano E, et al.
Biochem Biophys Res Commun
. 2016 Jun;
477(1):62-67.
PMID: 27282480
Bromodomains are epigenetic readers that specifically bind to the acetyl lysine residues of histones and transcription factors. Small molecule BET bromodomain inhibitors can disrupt this interaction which leads to potential...
7.
Duffy B, Liu S, Martin G, Wang R, Hsia M, Zhao H, et al.
Bioorg Med Chem Lett
. 2015 May;
25(14):2818-23.
PMID: 26022843
Bromodomains are key transcriptional regulators that are thought to be druggable epigenetic targets for cancer, inflammation, diabetes and cardiovascular therapeutics. Of particular importance is the first of two bromodomains in...
8.
Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, et al.
Atherosclerosis
. 2014 Jul;
236(1):91-100.
PMID: 25016363
Despite the benefit of statins in reducing cardiovascular risk, a sizable proportion of patients still remain at risk. Since HDL reduces CVD risk through a process that involves formation of...
9.
Bhadury J, Nilsson L, Muralidharan S, Green L, Li Z, Gesner E, et al.
Proc Natl Acad Sci U S A
. 2014 Jul;
111(26):E2721-30.
PMID: 24979794
The bromodomain and extraterminal (BET) domain family of proteins binds to acetylated lysines on histones and regulates gene transcription. Recently, BET inhibitors (BETi) have been developed that show promise as...
10.
McLure K, Gesner E, Tsujikawa L, Kharenko O, Attwell S, Campeau E, et al.
PLoS One
. 2014 Jan;
8(12):e83190.
PMID: 24391744
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of...